Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20080348 | 0.86 | KMT2A (0.52) | HTR3AKMT2AL3MBTL1TSHRMEN1 | |
| SCHEMBL17176399 | 0.86 | HTR3A (0.57) | HTR3AKMT2ATSHRALDH1A1LMNA | |
| SCHEMBL15557435 | 0.84 | HTR3A (0.56) | HTR3A | |
| SCHEMBL4355585 | 0.83 | HTR3A (0.55) | HTR3AL3MBTL1TSHR | |
| SCHEMBL17170671 | 0.82 | HTR3A (0.57) | HTR3AL3MBTL1TSHRALDH1A1LMNA | |
| SCHEMBL23812548 | 0.82 | HTR3A (0.53) | HTR3AKMT2AL3MBTL1TSHRMEN1 | |
| SCHEMBL30416390 | 0.79 | HTR3A (0.52) | HTR3AKMT2AL3MBTL1TSHRMEN1 | |
| SCHEMBL23812575 | 0.79 | KMT2A (0.53) | HTR3AKMT2AL3MBTL1TSHRMEN1 | |
| SCHEMBL30417766 | 0.79 | HTR3A (0.51) | HTR3ALMNA | |
| SCHEMBL20080410 | 0.77 | HTR3A (0.51) | HTR3AKMT2AL3MBTL1TSHRMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA CALIFORNIA, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | HTR3A 1/4885KMT2A 2286/4885L3MBTL1 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.